摘要
目的分析生长抑素不同给药时机治疗急性胰腺炎的疗效及血浆二胺氧化酶活性。方法选择首都医科大学附属北京友谊医院急诊科收入治疗的急性胰腺炎患者96例为观察对象,54例轻中症患者依据生长抑素给药时间是否大于24 h分为A组(<24 h)、B组(≥24 h),42例重症患者依据生长抑素给药时间是否大于24 h分为C组(<24 h)、D组(≥24 h),回顾性分析不同给药时机对临床疗效的影响。结果A组临床总效率96.30%高于B组,C组临床总效率85.71%高于D组(P<0.05)。A组腹痛及腹胀缓解时间、平均住院时间较B组短(P<0.05);2组并发症发生率比较(P>0.05)。C组腹痛及腹胀缓解时间、平均住院时间较D组短(P<0.05);2组并发症发生率比较(P>0.05)。治疗后,A组血浆二胺氧化酶活性低于B组,C组血浆二胺氧化酶活性低于D组(P<0.05)。A组与B组不良反应发生率(P>0.05)。C组与D组不良反应发生率(P>0.05)。结论生长抑素于急性胰腺炎发病后24 h内给药可有效提高临床疗效,缩短治疗时间,促进肠黏膜屏障功能改善,安全性较高。
Objective To analyze the efficacy of different administration timing of somatostatin in the treatment of acute pancreatitis and plasma diamine oxidase activity.Methods A total of 96 patients with acute pancreatitis treated in Department of Emergency,Beijing Friendship Hospital,Capital Medical University were selected as observation subjects.Of them,54 patients with mild and moderate disease were divided into group A(<24 h)and group B(≥24 h)according to whether the administration time of somatostatin was greater than 24 h,and 42 patients with severe disease were divided into group C(<24 h)and group D(≥24 h)according to whether the administration time of somatostatin was greater than 24 h.The impact of different administration timing on clinical efficacy was analyzed retrospectively.Results The total clinical efficacy of group A was 96.30%,which was higher than that of group B,and the total clinical efficacy of group C was 85.71%,which was higher than that of group D(P<0.05).The remission time of abdominal pain and abdominal distension and average length of hospital stay in group A were shorter than those in group B(P<0.05).There was no significance in the incidence of complications between the two groups(P>0.05).The remission time of abdominal pain and abdominal distension and the average length of hospital stay in group C were shorter than those in group D(P<0.05).No significant difference was found in the incidence of complications between the two groups(P>0.05).After treatment,the plasma diamine oxidase activity was lower in group A than in group B,and lower in group C than in group D(P<0.05).There was no significant difference in the incidence of adverse reactions between group A and group B(P>0.05)as well as between group C and group D(P>0.05).Conclusion Administration of somatostatin within 24 h after the onset of acute pancreatitis can effectively improve the clinical efficacy,shorten the duration of treatment,and promote the improvement of intestinal mucosal barrier function,with good safety.
作者
许东明
XU Dong-ming(Department of Emergency,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)
出处
《河北医科大学学报》
2025年第2期172-176,共5页
Journal of Hebei Medical University
基金
国家自然科学基金(82274131)。
关键词
胰腺炎
生长抑素
治疗结果
pancreatitis
somatostatin
treatment outcome
